A 2-stage trial testing a new and acclaimed HIV-prevention drug has shown almost unthinkable results of no new infections among a sample size of 3,200 participants. Called PURPOSE 1, the aim of the first trial was testing a subcutaneous injection of the drug Lenacapavir given twice a year to people in a high-HIV-incidence country, which […]
The post Staggering Results Show HIV-Transmission Reduced 100% with Twice-Yearly Lenacapavir Injection appeared first on Good News Network.
